Stephen Anastasiou

Author: NON-EXECUTIVE DIRECTOR - B.Sc.(Hons), Grad. Dip MK

Mr Anastasiou has extensive experience in general management, marketing and strategic planning in the healthcare industry. Formerly with KPMG, his breadth of industry experience incorporates diagnostics, ethical, hospital, dental and OTC products with local and international companies such as Bristol-Myers Squibb. He is a director and shareholder of a number of unlisted private companies covering a variety of industry sectors including healthcare and funds management.

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Payment Options

Contact Information

Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Phone: +613 8892 4854
Fax: +613 9899 8533

Categories

Information

Stephen Anastasiou

Partners

Secure Shopping

Get Connected

About Us

Information

Payment Options

Contact Information